A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma.
J Erinjeri, E Rosenbaum, K Seier, M Bradic, S Movva, M M Gounder, P Chi, B A Nacev, J E Chan, V Avutu, M Biniakewitz, S Jasnani, M Duchemin, R Desir, P Wong, S Hwang, C R Antonescu, L-X Qin, W D Tap, S P D'Angelo, M L Keohan, C M Kelly, M A Dickson
ESMO open 2025;10(8):105522